

Franco Muggia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7517788/franco-muggia-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14
papers

227
citations

8
h-index

15
g-index

15
ext. papers

261
ext. citations

4.7
avg, IF

4.02
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 14 | Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 741-751 | 3.5 | 12 |
| 13 | Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. <i>Gynecologic Oncology Reports</i> , 2020 , 34, 100655 | 1.3 | 1 |
| 12 | Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18268-e18268 | 2.2 | |
| 11 | Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 57-67 | 4.4 | 12 |
| 10 | Platinum type is key in determining degree of neuropathy. <i>Gynecologic Oncology Reports</i> , 2018 , 26, 32 | 1.3 | |
| 9 | Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1124-TPS1124 | 2.2 | 3 |
| 8 | Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope. <i>American Journal of Pathology</i> , 2016 , 186, 1649-61 | 5.8 | 7 |
| 7 | Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. <i>Kidney International</i> , 2014 , 85, 213 | 9.9 | 11 |
| 6 | BRCAnessdand its implications for platinum action in gynecologic cancer. <i>Anticancer Research</i> , 2014 , 34, 551-6 | 2.3 | 48 |
| 5 | Bevacizumab in ovarian cancer: unanswered questions. <i>Drugs</i> , 2012 , 72, 931-6 | 12.1 | 6 |
| 4 | Principles of Systemic Therapy 2009 , 27-40 | | |
| 3 | Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 631-41 | | 17 |
| 2 | Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck. <i>Cancer</i> , 1986 , 57, 706-10 | 6.4 | 9 |
| 1 | Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). <i>Cancer</i> , 1982 , 49, 1555-60 | 6.4 | 23 |